Drug facts
MoleculeCabozantinib (Cabometyx)
Generics already compete: 1 maker on the market. 3 A-rated products from 1 maker substitute at the counter.
Cometriq was first approved by the FDA on 11/29/2012 under NDA 203756; the application holder is Exelixis Inc.
Holder Exelixis IncApplication NDA 203756Approved 11/29/2012
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,928days until the latest Cometriq patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved11/29/2012
Last patent02/10/2032
20132016201920222025202820312034
- Latest patent
- 02/10/2032Cometriq Orange Book
- Later patents, other products
- Cabometyx 07/09/2033 Orange Book
02Competition
- Generics
- 1 generic maker Orange Book
- Staged generics
- 1 passed FDA review, awaiting market entry FDA
- First generic approved
- 08/14/2026 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Cabozantinib profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Exelixis Inc Orange Book
- Application
- NDA 203756 Orange Book
- First approved
- 11/29/2012 Orange Book
- Dosage forms
- capsule; tablet
- Routes
- oral
- Other brand names
- Cometriq
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.